Spanish pharmaceutical company PharmaMar said on 26 January 2021 that that peer reviewed journal, Science, has published a paper that confirms that the company's drug Plitidepsin has a "potent preclinical efficacy" against COVID-19, Reuters news agency reported on Tuesday.
In a statement, PharmaMar said the Science paper reported that a study carried out in vitro and in vivo by a team of scientists in New York, San Francisco and Paris showed the drug leads to a reduction of viral replication, resulting in a 99% reduction of viral loads in the lungs of Plitidepsin-treated animals.
PharmaMar quoted Science as saying: "We believe that our data and the initial positive results from PharmaMar's clinical trial suggests that Plitidepsin should be strongly considered for expanded clinical trials for the treatment of COVID-19."
Reportedly, Plitidepsin, already authorised in some markets to treat tumours, blocks a protein associated with the COVID-19 virus. Toxicity of the drug is well known and the doses used in COVID-19 trials are well tolerated in humans.
PharmaMar added that it was in talks with various regulatory agencies to start Phase III trials.
Endo to share PFI and PFA data at American Orthopaedic Foot & Ankle Society Annual Meeting
Diamyd Medical secures Eurasian patent for insulin-based antigen therapy in type 1 diabetes
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amgen and Kyowa Kirin release rocatinlimab study results in atopic dermatitis